Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 13/20 | 0.48 |
| ▸ | TYK2 | P29597 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462406 | 1.00 | F10 (0.49) | F10PTGS2TYK2JAK2JAK1 | |
| SCHEMBL22650398 | 0.91 | F10 (0.41) | F10PTGS2TYK2JAK2JAK1 | |
| SCHEMBL12280261 | 0.86 | PIK3CA (0.43) | F10PTGS2PIK3CAPIK3CDPIK3CG | |
| SCHEMBL20038363 | 0.83 | PTGS2 (0.47) | F10PTGS2TYK2JAK2JAK1 | |
| SCHEMBL28362833 | 0.83 | F10 (0.53) | F10PTGS2 | |
| SCHEMBL3297140 | 0.83 | PTGS2 (0.48) | F10PTGS2TYK2JAK2JAK1 | |
| SCHEMBL8285973 | 0.83 | PTGS2 (0.48) | F10PTGS2TYK2JAK2JAK1 | |
| SCHEMBL30253118 | 0.83 | PTGS2 (0.48) | F10PTGS2TYK2JAK2JAK1 | |
| SCHEMBL24156707 | 0.80 | PIK3CA (0.47) | F10PTGS2TYK2JAK2JAK1 | |
| SCHEMBL30253079 | 0.80 | PIK3CA (0.47) | F10PTGS2TYK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | ALUMIS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230021554-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-4019518-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114364675-A | CDK inhibitors | 上海齐鲁锐格医药研发有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3110820-B1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11053219-B2 | Substituted pyridines as TYK2 inhibitors | ESKER THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200354338-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2020-11-12 | — | — | US | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3029031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-9340540-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340540-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2361902-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053219-B2 | Substituted pyridines as TYK2 inhibitors | TYK2, JAK1, PDXK | F10 2581/4885PTGS2 1498/4885TYK2 1/4885 |
| US-20230021554-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | F10 3828/4885PTGS2 3225/4885TYK2 1/4885 |
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | JAK3, JAK2, JAK1 | F10 2780/4885PTGS2 2072/4885TYK2 51/4885 |
| US-20230023761-A1 | SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS | TYK2, JAK1, PDXK | F10 3664/4885PTGS2 2520/4885TYK2 1/4885 |
| US-20200354338-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | F10 3828/4885PTGS2 3225/4885TYK2 1/4885 |
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | F10 3997/4885PTGS2 3848/4885TYK2 1/4885 |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | F10 2980/4885PTGS2 702/4885TYK2 1/4885 |
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | F10 3527/4885PTGS2 2925/4885TYK2 1069/4885 |
| US-11731956-B2 | Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors | TYK2, JAK1, JAK3 | F10 2661/4885PTGS2 1993/4885TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.